Login / Signup

Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.

Manon L M PrinsJohan L van der PlasMaurits F J M VissersCécile L BerendsGaby TreschMarianne SoergelElena FernándezNikita van den BergeDaniël DuijsingsChristof ZittVaia StavropoulouMaya ZimmermannRoxana F DrakeJacobus BurggraafGeert H GroeneveldIngrid M C Kamerling
Published in: British journal of clinical pharmacology (2022)
Single-dose intravenous administration of 225 or 600 mg of ensovibep appeared safe and well tolerated in patients with mild-to-moderate COVID-19. Ensovibep showed favourable pharmacokinetics in patients and the pharmacodynamic results warrant further research in a larger phase 2/3 randomized-controlled trail.
Keyphrases